Actavis and Allergan have cleared the last hurdle antitrust hurdle closing their $66 billion merger agreement.
The European Commission has signed off on the tie-up, the companies said Monday. And with that, they expect the acquisition to wrap up Tuesday, they said in a statement.
While the drugmakers haven’t until now had all of their official OK’s to tie the knot, the integration process has been underway for awhile. Actavis quickly started rebranding the company as a “growth pharma”–to set it apart from the slow-growth Big Pharma companies it will join in the industry’s global top 10 when the deal closes.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
European Commission Approves Nippon Steel’s $14.9 Billion Buyout of U.S. Steel
May 6, 2024 by
CPI
Banco Sabadell Rejects Rival BBVA Merger Proposal
May 6, 2024 by
CPI
Novo Nordisk Foundation’s Acquisition Faces Regulatory Hurdles
May 6, 2024 by
CPI
Microsoft’s MAI-1 to Compete with Google and OpenAI in AI Language Models
May 6, 2024 by
CPI
Qantas Settles ‘Ghost Flights’ Case With Australian Watchdog for $120 Million
May 6, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI